- Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicineChristian Grimstein
Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US FDA, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
Ther Deliv 2:369-81. 2011..Incorporating pharmacogenomics into drug development of mAbs and igFPs will improve treatment efficacy, and may allow prediction of adverse events. Thus, a promising future of personalized medicine for these therapeutics is predicted...